

ErbB2-Mediated Src and Signal Transducer and Activator of Transcription 3 Activation Leads to Transcriptional Up-Regulation of p21^{Cip1} and Chemoresistance in Breast Cancer Cells

Valerie S. Hawthorne, Wen-Chien Huang, Christopher L. Neal, Ling-Min Tseng, Mien-Chie Hung, and Dihua Yu

Department of Molecular and Cellular Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

Abstract

Overexpression of the ErbB2 receptor tyrosine kinase is prevalent in ~30% of human breast cancers and confers Taxol resistance. Our previous work has shown that ErbB2 inhibits Taxol-induced apoptosis in breast cancer cells by transcriptionally up-regulating p21^{Cip1}. However, the mechanism of ErbB2-mediated p21^{Cip1} up-regulation is unclear. Here, we show that ErbB2 up-regulates p21^{Cip1} transcription through increased Src activity in ErbB2-overexpressing cells. Src activation further activated signal transducer and activator of transcription 3 (STAT3) that recognizes a SIE binding site on the p21^{Cip1} promoter required for ErbB2-mediated p21^{Cip1} transcriptional up-regulation. Both Src and STAT3 inhibitors restored Taxol sensitivity in resistant ErbB2-overexpressing breast cancer cells. Our data suggest that ErbB2 overexpression can activate STAT3 through Src leading to transcriptional up-regulation of p21^{Cip1} that confers Taxol resistance of breast cancer cells. Our study suggests a potential clinical application of Src and STAT3 inhibitors in Taxol sensitization of ErbB2-overexpressing breast cancers. (Mol Cancer Res 2009;7(4):592–600)

Introduction

Overexpression of p185^{ErbB2} (ErbB2, HER-2, neu) occurs in ~20% to 30% of breast cancer patients and results in increased incidence of metastasis and chemoresistance (1, 2). Previously, we and others have shown that ErbB2 overexpression confers paclitaxel (Taxol) resistance in breast cancer cells (3, 4). Our

further studies showed that resistance occurs through ErbB2 direct phosphorylation of the cyclin-dependent kinase p34^{Cdc2} in a kinase-dependent manner and transcriptional up-regulation of p21^{Cip1} in an ErbB2 kinase-independent manner; however, the exact mechanism of how ErbB2 transcriptionally up-regulates p21^{Cip1} is not yet defined (5, 6).

CDKN1A encodes a 21 kDa protein, p21^{Cip1}, known for its role as a cyclin-dependent kinase inhibitor and p53-inducible gene (7-9). However, p21^{Cip1} up-regulation can also occur through p53-independent mechanisms including growth factor stimulation (10). p21^{Cip1} partially governs the cell cycle at multiple checkpoints including the G₁-S and the G₂-M transitions (11). Increased levels of p21^{Cip1} at the G₂-M transition result in a mitotic delay through the binding and inactivation of the Cdc2/cyclin B complex (6). In addition, increased p21^{Cip1} levels may reduce Taxol sensitivity (12).

The p21^{Cip1} promoter contains multiple transcription factor binding sites including SIE sequences, which are consensus binding sites for signal transducer and activator of transcription (STAT) proteins (9, 13). STAT proteins are a family of transcription factors found latent in the cytoplasm. On activation by both receptor and non-receptor tyrosine kinases, STATs are phosphorylated and translocated to the nucleus, thereby activating downstream genes (14). Several STAT proteins are reported to have an oncogenic role (15). Particularly, STAT3 has been shown to be persistently activated in multiple human carcinomas, including breast cancers (15, 16).

We, along with others, have shown that ErbB2 activates STAT and can signal through STAT responsive elements (17, 18). It has been reported previously that ErbB2 and STAT3 may not directly interact; however, ErbB2-mediated activation of STAT3 may occur through the participation of other non-receptor tyrosine kinases (19). Our previous studies have shown that ErbB2 overexpression leads to a Src-ErbB2 constitutive association and elevated activated Src levels (20, 21). We therefore investigated whether ErbB2-mediated Src activation may regulate activation and downstream signaling of STAT3 in breast cancer cells and whether activation of this pathway is critical for ErbB2 transcriptional up-regulation of p21^{Cip1} and ErbB2-mediated chemoresistance. In our study, we provide evidence to show that STAT3 activation, through ErbB2 and Src, indeed led to transcriptional up-regulation of p21^{Cip1} and targeting either STAT3 or Src kinase sensitized ErbB2-overexpressing breast cancer cells to Taxol.

Received 7/4/08; revised 12/29/08; accepted 1/2/09; published online 4/16/09.

Grant support: NIH grants P30-CA16672 (M. D. Anderson Cancer Center), PO1-CA0099031 project 4, 1R01-CA109570, 1R01CA119127, and P50 CA116199 project 4 (D. Yu).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: D. Yu is the Nylene Eckles Distinguished Professor in Breast Cancer Research.

Current address for L-M. Tseng: Taipei-Veterans General Hospital, Taipei 112, Taiwan.

Requests for reprints: Dihua Yu, Department of Molecular and Cellular Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 108, Houston, TX 77030. Phone: 713-792-3636; Fax: 713-792-4454. E-mail: dyu@mdanderson.org

Copyright © 2009 American Association for Cancer Research.

doi:10.1158/1541-7786.MCR-08-0316

Results

Hyperactivated STAT3 Binds to the STAT-SIE on the p21^{Cip1} Promoter in ErbB2-Overexpressing Cells

To investigate the mechanism of ErbB2-mediated p21^{Cip1} transcriptional up-regulation, we examined the 2.4 kb promoter of p21^{Cip1}. Among the transcription factor binding sites, we focused on the SIE1 sequence, previously identified as a STAT1/3 binding site, located at -679 to -669 bp, because we have shown previously that ErbB2 overexpression can lead to STAT3 activation (18). To directly test whether the STAT binding site on the p21^{Cip1} promoter was required for ErbB2-mediated transcriptional up-regulation, we generated four different p21^{Cip1} promoter-driven luciferase reporters with or without STAT binding site mutations: a full-length 2.4 kb wild-type promoter (pGL3-p21-2400), a 5' truncated promoter containing the SIE1 site (pGL3-p21-741), a 5' truncated promoter with the SIE1

sequence deleted (pGL3-p21-643ΔSIE), and a full-length promoter with SIE1 sequence mutations (pGL3-p21-2400mSIE). We transiently transfected each reporter construct into MDA-MB-435 human breast cancer cells stably overexpressing ErbB2 (435.ErbB2) or control vector (435.Vec) and measured the luciferase activity. Increased luciferase activities were detected in ErbB2 high-expressing 435.ErbB2 cells transfected with the pGL3-p21-2400 and pGL3-p21-741 promoters. In contrast, there was no increase in luciferase activity when 435.ErbB2 cells were transfected with pGL3-p21-643ΔSIE and pGL3-p21-2400mSIE (Fig. 1A), indicating that the SIE1 site is necessary for ErbB2-mediated p21 transcriptional up-regulation. Next, to assure STAT proteins are activated by ErbB2 overexpression and contribute to p21 up-regulation, we detected phosphorylated STAT3 and STAT1 in a panel of breast cancer cell lines (Fig. 1B). SKBR3, an endogenously




FIGURE 1. Constitutive activation of STAT3 in ErbB2-overexpressing cells results in p21^{Cip1} transcriptional up-regulation. **A.** Left, schematic diagram of the 5' promoter region of the p21 gene. White boxes, STAT SIE location on promoter; black box, mutated SIE. Right, luciferase activity of extracts prepared from 435.Vec and 435.ErbB2 cells transfected with the indicated p21^{Cip1} promoter reporter constructs. Columns, luciferase activity standardized to vector control for each construct; bars, SD. **B.** Lysates from SKBR3 along with MDA-MB-435 and MDA-MB-231 breast cancer cells stably transfected with either control vector or wild-type ErbB2 were analyzed by Western blotting with the indicated antibodies. **C.** Nuclear extracts were collected from ErbB2 stable transfectants and vector control cells and SKBR3 cells for electrophoretic mobility shift assay analysis. Arrow, STAT protein-DNA complexes. Asterisk, addition of non-radiolabeled competitor probe. **D.** Chromatin immunoprecipitation assay for SIE p21^{Cip1} promoter sequence using antibodies against histone and STAT3 in ErbB2-overexpressing cells. Histone and IgG immunoprecipitation served as positive and negative controls, respectively. Input represents 10% of the total.

overexpressing ErbB2 breast cancer cell line, had increased phosphorylation of STAT3 but not STAT1. Similarly, the ErbB2 transfectants 435.ErbB2 and 231.ErbB2 showed increased levels of phosphorylated STAT3 but not STAT1 compared with the ErbB2 low-expressing 435.Vec and 231.Vec cells. Furthermore, increased STAT3 phosphorylation in ErbB2-overexpressing cells correlated with increased p21^{Cip1} protein levels (Fig. 1B). These data suggest that STAT3 is activated in ErbB2-overexpressing cells and activation of STAT3 may play a role in ErbB2-mediated p21^{Cip1} up-regulation.

STAT proteins (STAT1 and STAT3) have been shown to bind to the SIE in the p21 promoter (13, 22). To determine whether activated STAT3 in ErbB2 high-expressing cells may have increased binding to the SIE1 region on the p21^{Cip1} promoter, we performed an electrophoretic mobility shift assay. Compared to ErbB2 low-expressing cells with low STAT3 activity, elevated STAT:SIE1 DNA binding to the -685 to -665 bp region of the p21^{Cip1} promoter was detected in the ErbB2-overexpressing breast cancer cell lines (435.ErbB2, 231.ErbB2, and SKBR3) with activated STAT3 (Fig. 1C). To determine whether STAT3 bound to the p21^{Cip1} promoter in these cells *in vivo*, we performed a chromatin immunoprecipitation assay. Chromatin fragments were immunoprecipitated from ErbB2 high-expressing cell lines using anti-rabbit IgG, anti-histone, or anti-STAT3 antibodies. PCR of coprecipitated DNA using primers corresponding to the SIE1 site of p21^{Cip1} promoter detected signals from the anti-histone positive control and anti-STAT3 precipitated DNA but not from anti-rabbit IgG (Fig. 1D). These data indicated that high ErbB2 expression results in increased STAT3:SIE1 DNA-binding activity, which correlated with increased p21^{Cip1} protein expression.

STAT3 Is Required for ErbB2-Mediated p21^{Cip1} Transcriptional Up-Regulation

To evaluate whether STAT3 was required for p21^{Cip1} up-regulation, we transfected ErbB2 high-expressing 435.ErbB2 and 231.ErbB2 cells with STAT3 antisense or control mismatch oligonucleotides. STAT3 protein levels were decreased in antisense-treated cells, which corresponded to decreased p21^{Cip1} protein levels (Fig. 2A). To further investigate whether inhibition of STAT3 expression led to reduced p21^{Cip1} expression at the transcriptional level, we treated ErbB2 high-expressing cells with STAT3 antisense or mismatch oligonucleotides and cotransfected with the 2.4 kb wild-type p21 promoter reporter gene. Luciferase assays showed decreased p21^{Cip1} promoter activity by STAT3 antisense treatment compared with mismatch-treated control cells (Fig. 2B). These experiments revealed that both the STAT3 protein and the SIE1 binding site on the p21^{Cip1} promoter are required for ErbB2-mediated p21^{Cip1} transcriptional up-regulation in breast cancer cells.

ErbB2, Src, and STAT3 Form a Complex in ErbB2-Overexpressing Cells

Our laboratory has shown that Src is activated and constitutively associated with the ErbB2 receptor in ErbB2-overexpressing breast cancer cells (20). Src has been implicated to activate STAT in mammary epithelial cells (23, 24). To investigate whether the activated Src in ErbB2-overexpressing breast cancer cells is involved in STAT3 activation, we first examined




FIGURE 2. p21^{Cip1} transcriptional activation by ErbB2 is dependent on STAT3 protein. **A.** 435.ErbB2 and 231.ErbB2 cells treated with 300 nmol/L mismatch (MM) or STAT3 antisense (AS) oligonucleotides. Cells were harvested 5 d post-transfection and analyzed by Western blot with the indicated antibodies. **B.** Standardized firefly luciferase activity of the wild-type p21 promoter (pGL3-p21-2400) reporter plasmid in 435.ErbB2 and 231.ErbB2 cells treated with either STAT3 mismatch or antisense oligonucleotides. Fold reduction was determined by standardizing to mismatch control-treated sample for each cell line. Bars, SD.

whether ErbB2, STAT3, and Src may coexist in a hetero-complex. Immunoprecipitation of ErbB2, STAT3, or Src in 435.ErbB2 cells followed by Western blotting of ErbB2, STAT3, and Src detected a hetero-complex containing the three proteins (Fig. 3A). A similar result was also seen in SKBR3 cells (Fig. 3B). The data suggest that formation of the signaling complex consisting of ErbB2, Src, and STAT3 in ErbB2-overexpressing cells may contribute to ErbB2-mediated up-regulation of p21^{Cip1}.

Src Is Required for p21^{Cip1} Up-Regulation in ErbB2-Overexpressing Cells

To determine whether ErbB2-mediated Src activation was required for ErbB2-mediated STAT3 activation and subsequent p21^{Cip1} up-regulation, we treated ErbB2-overexpressing cells (SKBR3 and 435.ErbB2) with the Src family kinase inhibitor PP2 and examined STAT3 phosphorylation and p21^{Cip1} expression. Treatment of both SKBR3 and 435.ErbB2 cells with PP2 resulted in a decrease of STAT3 phosphorylation and reduction in p21^{Cip1} protein levels when compared with PP3 control-treated cells (Fig. 4A). To determine whether PP2 treatment reduced p21 expression at the transcriptional level via inhibition

of STAT3, we cotransfected the wild-type 2.4 kb p21 promoter (pGL3-p21-2400) or the SIE STAT3 binding site mutant p21 promoter (pGL3-p21-2400mSIE)-driven luciferase reporters into 435.ErbB2 and SKBR3 cells that were treated with the Src inhibitor, PP2, or the control chemical, PP3. We found that PP2 repressed pGL3-p21-2400 promoter activity, whereas PP2 had no effect on pGL3-p21-2400mSIE promoter activity (Fig. 4B). In addition to chemical inhibitors, we cotransfected 435.ErbB2 and SKBR3 cells with a dominant-negative Src mutant or empty vector as control and repeated the assays described in Fig. 4A and B. Similar to PP2 treatment, dominant-negative Src mutant resulted in decreased phosphorylated STAT3, decreased total p21^{Cip1} protein levels, and reduced p21^{Cip1} promoter-driven luciferase activities compared with vector control transfection in ErbB2-overexpressing cells (Fig. 4C and D).

STAT3 Inhibition Restores Taxol Sensitivity in ErbB2-Overexpressing Cells

Our results indicated that ErbB2-overexpressing breast cancer cells up-regulate p21^{Cip1} through activation of STAT3. We have shown p21^{Cip1} up-regulation is important for ErbB2-mediated Taxol resistance (6). Therefore, we examined whether inhibiting STAT3 DNA binding by a STAT3 inhibitory peptide would sensitize ErbB2-overexpressing breast cancer cells to Taxol treatment. To validate the efficacy of the STAT3 peptide inhibitor, we performed an electrophoretic mobility shift assay using a STAT3 binding consensus sequence as a DNA probe and nuclear lysates collected from STAT3 inhibitor-treated

and control-treated 435.ErbB2 (Fig. 5A, *top*) and SKBR3 (Fig. 5A, *bottom*) cells. We observed a dramatic decrease in STAT3:DNA binding in STAT3 inhibitor peptide-treated cells, indicating that the STAT3 inhibitor effectively inhibited STAT3 binding to DNA (Fig. 5A). Next, ErbB2-overexpressing breast cancer cells were treated with either control peptide or STAT3 inhibitor peptide. The treatment resulted in a decrease in p21^{Cip1} protein levels (Fig. 5B, *inset*). Both 435.ErbB2 and SKBR3 cell lines treated with STAT3 inhibitor peptide plus Taxol showed more effective inhibition of cell growth when compared with control peptide plus Taxol-treated cells (Fig. 5B). Therefore, inhibition of STAT3 can sensitize ErbB2-overexpressing breast cancer cells to Taxol treatment.

Src Inhibition Restores Taxol Sensitivity in ErbB2-Overexpressing Cells

Because STAT3 is activated in ErbB2-overexpressing cells through Src activation, we investigated whether inhibiting Src activation may also sensitize ErbB2-overexpressing breast cancer cells to Taxol. 435.ErbB2 cells were treated with a clinically applicable Src inhibitor, AZD0530, or with DMSO solvent as a control (25). AZD0530 effectively inhibited Src phosphorylation without altering Src protein expression level (Fig. 6A). Furthermore, STAT3 phosphorylation was also reduced by AZD0530 treatment. Moreover, AZD0530 treatment reduced p21^{Cip1} expression (Fig. 6A). Similar results were also seen in SKBR3 cells (data not shown). To confirm Src inhibition by AZD0530 disrupted STAT3 binding to the p21^{Cip1} promoter, we performed a chromatin immunoprecipitation assay. PCR of




FIGURE 3. ErbB2, Src, and STAT3 form a complex in ErbB2-overexpressing cells. Whole-cell lysates from (A) 435.ErbB2 or (B) SKBR3 cells were immunoprecipitated (IP) with the indicated antibodies followed by immunoblot analysis for ErbB2, STAT3, and Src. Input lanes represent 10% of total protein immunoprecipitated. Asterisk, IgG heavy chain.




FIGURE 4. Src is required for ErbB2-mediated STAT3 activation and p21^{Cip1} up-regulation. **A.** ErbB2-overexpressing cells were treated with 5 μmol/L control (PP3) or Src inhibitor (PP2). Cell lysates were collected and analyzed by Western blotting. **B.** 435.ErbB2 and SKBR3 cells were transfected with the p21^{Cip1} reporter plasmids wild-type (pGL3-p21-2400) or SIE mutant (pGL3-p21-2400mSIE) and treated with 5 μmol/L PP3 or PP2 for 24 h. Cell lysates were collected and luciferase activities were measured and standardized by transfection efficiency using *Renilla* values. Bars, SD. **C.** Indicated cells were transfected with either vector control (*Vec*) or dominant-negative Src mutant (*pSRC-DN*) for 24 h. Lysates were analyzed by Western blotting. **D.** Cells were cotransfected with vector control or dominant-negative Src mutant plasmids and the pGL3-p21-2400 reporter plasmid. Luciferase activities were measured as in **C**.

STAT3 immunoprecipitated chromatin fragments indicated that AZD0530 treatment dramatically reduced STAT3 binding to the SIE site of the p21^{Cip1} promoter compared with DMSO-treated cells (Fig. 6B). We then treated the cells with AZD0530, Taxol, or AZD0530 plus Taxol. We found that AZD0530 sensitized the cells to Taxol treatment in both 435.ErbB2 and SKBR3 cells (Fig. 6C). Thus, Src inhibition in combination with Taxol treatment can more effectively inhibit ErbB2-overexpressing breast cancer cell proliferation.

Discussion

Our data showed that ErbB2 increases p21^{Cip1} levels by transcriptional up-regulation. ErbB2-mediated transcriptional up-regulation of target genes can occur through the increased

activation of transcription factors, such as STAT (26-29). In our model system, high expression of ErbB2 led to increased activated phosphorylation of STAT3 mediated by Src kinase downstream of ErbB2. Mutation of the SIE1 STAT3 binding site in the p21^{Cip1} promoter decreased p21^{Cip1} promoter activity. Likewise, inhibition of STAT3 or Src kinase activity reduced p21 expression at the transcriptional level and sensitized ErbB2-overexpressing breast cancer cells to Taxol treatment. Our data showed the requirement for STAT3 and Src activity in ErbB2-mediated p21^{Cip1} up-regulation and therapeutic resistance.

Previous studies have shown that STAT3 activation by Src is required for Src-mediated transformation (30-32). Constitutive activation of STAT3 by overexpression of ErbB2 has also been reported (19, 29, 33-35); however, the role of ErbB2-mediated

Src activation leading to STAT3 activation and subsequent p21^{Cip1} up-regulation is unique to our study. Our data showed that ErbB2, Src, and STAT3 are associated in a complex in ErbB2-overexpressing cells. Src association with STAT3 provides a previously unknown link between ErbB2 and STAT3 activation. Our data support a model whereby formation of this signaling complex consisting of ErbB2, Src, and STAT3 may drive constitutive expression of downstream targets.

Although the SIE1 site on the p21^{Cip1} promoter had originally been identified as a STAT1 binding site (13), others have reported that the SIE1 site on the p21^{Cip1} promoter may bind STAT3 (36-39). These differences could be a result of different cell backgrounds. In our system, both chromatin immunoprecipitation and Western blot experiments indicated that STAT3 bound the p21^{Cip1} promoter at the SIE1 site in ErbB2-overexpressing breast cancer cells. Furthermore, when STAT3 protein was decreased or inhibited, p21^{Cip1} expression and promoter activity was reduced. This indicated that STAT3 and the SIE1-STAT binding site are both required to drive transcription of the p21^{Cip1} gene in response to ErbB2 overexpression.

Increased activation of STAT3 has been shown to lead to chemotherapeutic resistance due to STAT3 up-regulation of Bcl-2, which resulted in apoptotic resistance of Taxol-treated cells (40). The essential role of STAT3 in oncogenesis supports the use of STAT-targeting inhibitors in combination with conventional chemotherapy; however, clinically relevant STAT inhibitors are not available. An alternative target in this pathway is Src kinase, which has been well documented to be associated with increased phosphorylation and activation of STAT3. Interestingly, in our model system, we observed a modest decrease in STAT3 phosphorylation after Src inhibition by AZD0530 treatment. A recent report showed that another Src inhibitor,

dasatinib, reduced STAT3 phosphorylation levels in only one of the lung cancer cell lines tested, whereas phosphorylation of STAT3 was not affected in the other cell lines (41). It has also been shown that dasatinib treatment in multiple cancer cell lines led to reduced STAT3 phosphorylation levels initially; however, after long-term treatment, STAT3 phosphorylation levels returned to basal levels, although Src was inhibited (42). This was explained by the activation of compensatory pathways (42). This may explain why AZD0530 as a single agent produced modest cell growth inhibition in our model system. Nevertheless, we have shown that AZD0530 treatment led to decreased STAT3 binding to the p21 promoter that corresponded with the sensitization to Taxol treatment. Together, our new findings showed that Src-mediated activation of STAT3 up-regulated p21^{Cip1} and this pathway is involved in Taxol resistance of ErbB2-overexpressing cells. The findings further provide a strong rationale for using either STAT3 or Src inhibition to sensitize Taxol response, especially in ErbB2-overexpressing breast cancer cells.

In conclusion, our data provided evidence on the pivotal role of Src-mediated STAT3 activation and subsequent p21^{Cip1} up-regulation in Taxol resistance of ErbB2-overexpressing breast cancer cells. Blockade of STAT3 DNA-binding activity and inhibition of Src activation led to decreased p21^{Cip1} expression and restoration of Taxol sensitivity. Currently in the oncology field, combinational targeted therapy is an area of intense investigation (43-45). Because the Src inhibitor, AZD0530, is currently used in clinical trials (25), patients with Taxol resistant tumors due to deregulation of the ErbB2-Src-STAT3-p21^{Cip1} pathway may benefit from personalized cancer care using combination treatment of Taxol plus AZD0530 to target this pathway.




FIGURE 5. Inhibition of STAT3 sensitized ErbB2-overexpressing breast cancer cells to Taxol. **A.** 435.ErbB2 and SKBR3 cells were treated with 50 μmol/L STAT3 inhibitory peptide or control peptide for 24 h. Nuclear extracts were then subjected to electrophoretic mobility shift assay. Band shifts indicated a STAT3 protein-DNA complex. Oct-1 protein-DNA binding serves as a loading control. **B.** 435.ErbB2 and SKBR3 cells were treated with control (CP) or STAT3 inhibitor peptide (SP; 100 μmol/L for 435.ErbB2 and 50 μmol/L for SKBR3) for 12 h. Cells were then treated with different concentrations of Taxol for 24 h. Cell growth inhibition was determined by MTS assay. Bars, SD. Inset, representative Western blot for p21^{Cip1} and β-actin (loading control) from cells treated with either control or STAT3 inhibitor peptide treatment (**, $P = 0.004$; *, $P = 0.016$, t test).




FIGURE 6. Inhibition of Src kinase sensitized ErbB2-overexpressing breast cancer cells to Taxol. **A.** 435.ErbB2 cells were treated as indicated for 18 h. Cell lysates were collected and analyzed by Western blot analysis for the indicated antibodies. Numbers, relative intensity of each band compared with the nontreated (NT) control. Total STAT3 was used as the loading control for both phospho-STAT3-Y705 and p21. **B.** 435.ErbB2 cells were treated with DMSO (control) or AZD0530 for 18 h. Chromatin immunoprecipitation assay for SIE p21^{Cip1} promoter sequence was done using antibodies against histone and STAT3. IgG and histone immunoprecipitation served as negative and positive controls, respectively. Input represents 10% of the total. **C.** 435.ErbB2 and SKBR3 cells were treated with DMSO only or AZD0530 (2 μmol/L) for 12 h. After 12 h, cell medium was replaced with medium containing either Taxol (50 nmol/L) only, AZD0530 only, or combination of Taxol and AZD0530. Cell growth inhibition was determined by MTS assay at 36 h. Results were normalized to DMSO controls (**, $P = 0.002$; *, $P = 0.013$, t test).

Materials and Methods

Cell Lines and Reagents

Human breast cancer cell lines MDA-MB-231 and SKBR3 were obtained from the American Type Culture Collection and

the MDA-MB-435 cell line was obtained from Dr. Janet Price (M. D. Anderson Cancer Center). There is evidence suggesting MDA-MB-435 is not a breast cancer-derived cell line; however, we have shown that MDA-MB-435 is most likely a breast epithelial cell line that has undergone lineage infidelity (46, 47). The vector control and wild-type *erbB2* stable transfectants, 435.Vec/435.ErbB2, were generated as described previously (48) and 231.Vec/231.ErbB2 was a generous gift from Dr. Patricia Steeg (NIH). All cells, except SKBR3, were grown in DMEM/F-12 (50/50) and supplemented with 8% fetal bovine serum. SKBR3 cells were grown in McCoy's 5A medium supplemented with 10% fetal bovine serum and 5% L-glutamine.

Inhibitors used include Src family kinase inhibitor 4-amino-5-(4-chlorophenyl)-7-(*t*-butyl)pyrazolo[3,4-*d*]pyrimidine (PP2) or control 4-amino-7-phenylpyrazolo[3,4-*d*]pyrimidine (PP3) for a final concentration of 50 μmol/L for 24 h (Calbiochem).

The Src/Abl kinase inhibitor *N*-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine (AZD0530) was a gift from AstraZeneca.

Plasmid Constructs

The pGL3-p21-2400 plasmid was generated by digestion of the WWP-Luc plasmid (9, 49) to yield the 2.4 kb p21^{Cip1} promoter region that was cloned into pGL3-basic vector (Promega). pGL3-p21-741 and pGL3-p21-643ΔSIE plasmid were made by PCR amplification of the pGL3-p21-2400 plasmid using primers 5'-AATTCTTCTGTTTCCTGGAGATCA-3' and 5'-TTTTTGGCGTCTTCCATGGTGGCTTT-3' and 5'-CTTAAGTTCAGTGGACCTCAATTT-3' and 5'-TTTTTGGCGTCTTCCATGGTGGCTTT-3', respectively, and cloned into pGL3-basic vector. pGL3-p21-2400mSIE plasmid was constructed using the QuikChange Site-directed mutagenesis kit (Stratagene) with primers 5'-CTCAATTCCCTCCAAGCTTGAAGCATGTGACAATC-3' and 5'-GATTGTACATGCTTCAAGCTTGGAGGGAATTGGAG-3'. The plasmid dominant-negative Src mutant has been described previously (21).

Luciferase Assays

Cells were grown to 60% confluence in six-well plates. Cells were then transfected with 0.5 μg of indicated plasmid and 0.05 μg of control *Renilla* plasmid using Lipofectamine (Invitrogen). Luciferase assays were done 24 h post-transfection using the Dual-Luciferase Assay Reporter System (Promega) according to the manufacturer's protocol.

Western Blot and Immunoprecipitation Analysis

Total cell lysates were collected in immunoprecipitation lysis buffer [20 mmol/L Tris (pH 7.5), 150 mmol/L NaCl, 1 mmol/L EDTA, 1 mmol/L EGTA, 1% Triton X-100, 2.5 mmol/L sodium pyrophosphate, 1 mmol/L β-glycerophosphate, 1 mmol/L sodium orthovanadate, protease inhibitor cocktail, 1 mmol/L phenylmethylsulfonyl fluoride]. Lysates were subjected to SDS-PAGE followed by transfer to nitrocellulose membranes. Membranes were incubated with the following antibodies: ErbB2 (Calbiochem); STAT1, STAT3, phospho-STAT3-pY705, and anti-p21^{Cip1} (Cell Signaling Technology), anti-Src (Santa Cruz Biotechnology), and β-actin (Sigma). Secondary antibody detection used Alexa Fluor

secondary antibodies (Invitrogen/Molecular Probes). Proteins were detected using the LI-COR Odyssey detection system.

For immunoprecipitation experiments, 500 μg protein was precleared with 30 μL protein G-agarose beads for 1 h at 4°C. Immunoprecipitation was done using 5 μg isotype IgG control (Millipore) or the indicated primary antibody at 4°C overnight followed by incubation with 40 μL protein G-agarose beads for 4 h. Immune complexes were washed with lysis buffer and immunoprecipitates were separated by SDS-PAGE followed by Western blotting.

Electrophoretic Mobility Shift Assay

Cell membranes were lysed [10 mmol/L HEPES (pH 7.9), 10 mmol/L KCl, 0.1 mmol/L EDTA, 0.4% NP-40] and nuclear extracts were prepared in nuclear extraction buffer [20 mmol/L HEPES (pH 7.9), 0.4 mol/L NaCl, 1 mmol/L EDTA]. Nuclear extracts (5 μg) were incubated in a reaction mixture containing a double-stranded, 5'-end radiolabeled, oligonucleotide sequence derived from the SIE1 site on the p21^{Cip1} promoter, 5'-AGCTCCTCCCGGAAGCATG-3'. Cold competitor reactions included 2 pmol unlabeled double-stranded probe that was incubated for 30 min at room temperature in a 50-fold molar excess to the radiolabeled probe. All reactions were then incubated for 15 min at 37°C. Reaction complexes were resolved on a 5% nondenaturing polyacrylamide gel, dried, and exposed to film overnight at -80°C.

Chromatin Immunoprecipitation Assays

Chromatin immunoprecipitation assays were done based on the protocol from the chromatin immunoprecipitation assay kit (Millipore) with minor modifications. Briefly, soluble chromatin solutions from 1% formaldehyde fixed and sonicated cells were precleared and then immunoprecipitated with 5 μg isotype IgG, histone H1 (Santa Cruz Biotechnology), or STAT3 (Santa Cruz Biotechnology) antibodies overnight at 4°C. Immune complexes were precipitated with protein Sepharose A beads (GE Healthcare). Complexes were washed extensively and eluted, and proteins were removed.

Coprecipitated DNA (2 μL) was analyzed by PCR (30-35 cycles) using specific primers, 5'-AATTCTTCTGTTCCCTG-GAGATCA-3' and 5'-AAATTGAGGTCCACTGAACT-TAAG-3', to the STAT3 binding region (SIE1) of the p21^{Cip1} promoter. PCR products were resolved on a 2% TAE agarose gel stained with ethidium bromide.

STAT3 Antisense

Oligonucleotides against STAT3 were synthesized using phospho-isothiolate modifications (indicated by lowercase as follows: mismatch oligonucleotide 5'-aaaAAGAGGCCT-GATTgcc-3' and antisense oligonucleotide 5'-aaaAAGTGC-CCAGATTgcc-3'). Cells were grown to 40% confluence on day 1 and transfected twice (days 1 and 3) with 200 nmol/L of either mismatch or antisense oligonucleotide in serum-free Opti-MEM using Lipofectamine Plus (Invitrogen). Cells were harvested in lysis buffer on day 5.

Taxol Sensitivity and Cell Proliferation Assay

SKBR3 and 435.ErbB2 cells were seeded in 96-well plates at a density of 5×10^3 per well in 100 μL culture medium. After 24 h of adherence, medium was aspirated and replaced

with medium containing control or STAT3 inhibitor peptide (Calbiochem) concentrations of 100 $\mu\text{mol/L}$ for 435.ErbB2 and 50 $\mu\text{mol/L}$ for SKBR3 continuing for additional 12 h. Cells were then treated with different concentration of paclitaxel (Taxol) for 24 h. For Src inhibition, cells were treated with 2 $\mu\text{mol/L}$ AZD0530 for 12 h followed by Taxol treatment for 24 h. Viable cells were determined by CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay kit according to the manufacturer's protocol (Promega).

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

We thank Dr. Jun Yao for valuable discussion and Nina T. Nguyen for critical reading of the article.

References

1. Yu D, Hung MC. Role of erbB2 in breast cancer chemosensitivity. *Bioessays* 2000;22:673-80.
2. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/*neu* proto-oncogene in human breast and ovarian cancer. *Science* 1989;244:707-12.
3. Witters LM, Santala SM, Engle L, Chinchilli V, Lipton A. Decreased response to paclitaxel versus docetaxel in HER-2/*neu* transfected human breast cancer cells. *Am J Clin Oncol* 2003;26:50-4.
4. Yu D, Liu B, Jing T, et al. Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to Taxol. *Oncogene* 1998;16:2087-94.
5. Tan M, Jing T, Lan KH, et al. Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to Taxol-induced apoptosis. *Mol Cell* 2002;9:993-1004.
6. Yu D, Jing T, Liu B, et al. Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21^{Cip1}, which inhibits p34Cdc2 kinase. *Mol Cell* 1998;2:581-91.
7. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G₁ cyclin-dependent kinases. *Cell* 1993;75:805-16.
8. Zhang H, Xiong Y, Beach D. Proliferating cell nuclear antigen and p21 are components of multiple cell cycle kinase complexes. *Mol Biol Cell* 1993;4:897-906.
9. El-Deiry WS, Harper JW, O'Connor PM, et al. WAF1/CIP1 is induced in p53-mediated G₁ arrest and apoptosis. *Cancer Res* 1994;54:1169-74.
10. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. *Cancer Res* 1994;54:3391-5.
11. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. *Nature* 1993;366:701-4.
12. Schmidt M, Lu Y, Liu B, Fang M, Mendelsohn J, Fan Z. Differential modulation of paclitaxel-mediated apoptosis by p21^{Waf1} and p27^{Kip1}. *Oncogene* 2000;19:2423-9.
13. Chin YE, Kitagawa M, Su WC, You ZH, Iwamoto Y, Fu XY. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21^{WAF1/CIP1} mediated by STAT1. *Science* 1996;272:719-22.
14. Bromberg J, Darnell JE, Jr. The role of STATs in transcriptional control and their impact on cellular function. *Oncogene* 2000;19:2468-73.
15. Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. *Oncogene* 2000;19:2474-88.
16. Turkson J, Jove R. STAT proteins: novel molecular targets for cancer drug discovery. *Oncogene* 2000;19:6613-26.
17. Kami R, Jove R, Levitzki A. Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors. *Oncogene* 1999;18:4654-62.
18. Tan M, Lan KH, Yao J, et al. Selective inhibition of ErbB2-overexpressing breast cancer *in vivo* by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide. *Cancer Res* 2006;66:3764-72.
19. Ren Z, Schaefer TS. ErbB-2 activates Stat3 α in a Src- and JAK2-dependent manner. *J Biol Chem* 2002;277:38486-93.

20. Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. *Cancer Cell* 2004;6:117–27.
21. Tan M, Li P, Klos KS, et al. ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis. *Cancer Res* 2005;65:1858–67.
22. Bellido T, O'Brien CA, Roberson PK, Manolagas SC. Transcriptional activation of the p21(WAF1,CIP1,SDI1) gene by interleukin-6 type cytokines. A prerequisite for their pro-differentiating and anti-apoptotic effects on human osteoblastic cells. *J Biol Chem* 1998;273:21137–44.
23. Silva CM. Role of STATs as downstream signal transducers in Src family kinase-mediated tumorigenesis. *Oncogene* 2004;23:8017–23.
24. Olayioye MA, Beuvink I, Horsch K, Daly JM, Hynes NE. ErbB receptor-induced activation of Stat transcription factors is mediated by Src tyrosine kinases. *J Biol Chem* 1999;274:17209–18.
25. Hennequin LF, Allen J, Breed J, et al. N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. *J Med Chem* 2006;49:6465–88.
26. Loureiro RM, Maharaj AS, Dankort D, Muller WJ, D'Amore PA. ErbB2 overexpression in mammary cells upregulates VEGF through the core promoter. *Biochem Biophys Res Commun* 2005;326:455–65.
27. Mendoza-Gamboa E, Siwak DR, Tari AM. The HER2/Grb2/Akt pathway regulates the DNA binding activity of AP-1 in breast cancer cells. *Oncol Rep* 2004;12:903–8.
28. Galang CK, Garcia-Ramirez J, Solski PA, et al. Oncogenic Neu/ErbB-2 increases ets, AP-1, and NF- κ B-dependent gene expression, and inhibiting ets activation blocks Neu-mediated cellular transformation. *J Biol Chem* 1996;271:7992–8.
29. Fernandes A, Hamburger AW, Gerwin BI. ErbB-2 kinase is required for constitutive Stat 3 activation in malignant human lung epithelial cells. *Int J Cancer* 1999;83:564–70.
30. Bromberg JF, Horvath CM, Besser D, Lathem WW, Darnell JE, Jr. Stat3 activation is required for cellular transformation by v-src. *Mol Cell Biol* 1998;18:2553–8.
31. Odajima J, Matsumura I, Sonoyama J, et al. Full oncogenic activities of v-Src are mediated by multiple signaling pathways. Ras as an essential mediator for cell survival. *J Biol Chem* 2000;275:24096–105.
32. Turkson J, Bowman T, Garcia R, Caldenhoven E, De Groot RP, Jove R. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. *Mol Cell Biol* 1998;18:2545–52.
33. Carraway KL, III, Sweeney C. Co-opted integrin signaling in ErbB2-induced mammary tumor progression. *Cancer Cell* 2006;10:93–5.
34. DeArmond D, Brattain MG, Jessup JM, et al. Autocrine-mediated ErbB-2 kinase activation of STAT3 is required for growth factor independence of pancreatic cancer cell lines. *Oncogene* 2003;22:7781–95.
35. Guo W, Pylyayeva Y, Pepe A, et al. β_4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. *Cell* 2006;126:489–502.
36. Barre B, Avril S, Coqueret O. Opposite regulation of myc and p21^{waf1} transcription by STAT3 proteins. *J Biol Chem* 2003;278:2990–6.
37. Giraud S, Bienvenu F, Avril S, Gascan H, Heery DM, Coqueret O. Functional interaction of STAT3 transcription factor with the coactivator NcoA/SRC1a. *J Biol Chem* 2002;277:8004–11.
38. Lu S, Shen KC, Wang Y, Brooks SC, Wang YA. Impaired hepatocyte survival and liver regeneration in Atm-deficient mice. *Hum Mol Genet* 2005;14:3019–25.
39. Sinibaldi D, Wharton W, Turkson J, Bowman T, Pledger WJ, Jove R. Induction of p21^{WAF1/CIP1} and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling. *Oncogene* 2000;19:5419–27.
40. Real PJ, Sierra A, De Juan A, Segovia JC, Lopez-Vega JM, Fernandez-Luna JL. Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. *Oncogene* 2002;21:7611–8.
41. Song L, Morris M, Bagui T, Lee FY, Jove R, Haura EB. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. *Cancer Res* 2006;66:5542–8.
42. Johnson FM, Saigal B, Tran H, Donato NJ. Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects. *Clin Cancer Res* 2007;13:4233–44.
43. Lu CH, Wyzomierski SL, Tseng LM, et al. Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. *Clin Cancer Res* 2007;13:5883–8.
44. Hiscox S, Morgan L, Green T, Nicholson RI. Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer. *Endocr Relat Cancer* 2006;13:S53–9.
45. Stornio AM, Pegram MD, Overmoyer B, et al. Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer. *J Clin Oncol* 2008;26:3317–23.
46. Sellappan S, Grijalva R, Zhou X, et al. Lineage infidelity of MDA-MB-435 cells: expression of melanocyte proteins in a breast cancer cell line. *Cancer Res* 2004;64:3479–85.
47. Ross DT, Scherf U, Eisen MB, et al. Systematic variation in gene expression patterns in human cancer cell lines. *Nat Genet* 2000;24:227–35.
48. Yu D, Liu B, Tan M, Li J, Wang SS, Hung MC. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. *Oncogene* 1996;13:1359–65.
49. Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. *Science* 1990;249:912–5.

Molecular Cancer Research

ErbB2-Mediated Src and Signal Transducer and Activator of Transcription 3 Activation Leads to Transcriptional Up-Regulation of p21^{Cip1} and Chemoresistance in Breast Cancer Cells

Valerie S. Hawthorne, Wen-Chien Huang, Christopher L. Neal, et al.

Mol Cancer Res 2009;7:592-600.

Updated version Access the most recent version of this article at:
<http://mcr.aacrjournals.org/content/7/4/592>

Cited articles This article cites 49 articles, 23 of which you can access for free at:
<http://mcr.aacrjournals.org/content/7/4/592.full#ref-list-1>

Citing articles This article has been cited by 8 HighWire-hosted articles. Access the articles at:
<http://mcr.aacrjournals.org/content/7/4/592.full#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://mcr.aacrjournals.org/content/7/4/592>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.